Tiragolumab with atezolizumab and pemetrexed and carboplatin or cisplatin for previously untreated advanced non-small-cell lung cancer

Tiragolumab in combination with atezolizumab, pemetrexed and carboplatin or cisplatin is currently in development for patients with previously untreated locally advanced unresectable or metastatic programmed death-ligand 1 (PD-L1) selected non-small cell lung cancer (NSCLC). NSCLC makes up most lung cancers in the UK. Metastatic NSCLC is when the cancer has spread beyond the lung that was initially affected, most often to the liver, adrenal glands, bones, and the brain. Symptoms of lung cancer include cough, repeated chest infections, breathlessness, unexplained pain, weight loss or tiredness. However, patients may not always be symptomatic in the early stages. Most patients with NSCLC are diagnosed at the advanced/metastatic stage where curative treatment with surgery is unsuitable.